OUR FOCUS: SERVING PATIENTS
INOVIO has several clinical programs aimed at treating specific cancers, including glioblastoma multiforme (GBM), an aggressive malignancy of the brain (INO-5401 in partnership with REGENERON), as well as prostate cancer (INO-5151 in partnership with the Cancer Research Institute and the Parker Institute for Cancer Immunotherapy).
Glioblastoma Multiforme (GBM) is a devastating disease for both patients and caregivers. It is the most aggressive brain cancer and its prognosis is extremely poor, despite a limited number of new therapies approved over the last 10 years.1 More than 11,000 people in the U.S. get GBM each year, and more than 23,000 people in the U.S. have GBM. The median overall survival for patients receiving standard of care therapy is approximately 15 months1 and the average five-year survival rate is only 5.8% for urban residents and only 3.9% for rural residents.
Advancements on the Horizon for GBM
In June 2018, INOVIO dosed the first patient as part of a Phase 1/2 immuno-oncology trial in patients with newly diagnosed GBM. The trial is designed to evaluate INO-5401 and INO-9012, in combination with cemiplimab (REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals.
In November 2019, INOVIO announced positive interim Phase 2 results showing INO-5401 and INO-9012, in combination with the PD-1, delivered six months progression-free survival for the majority of patients.
American Association of Neurological Surgeons. Glioblastoma Multiforme. Available at aans.org. Accessed January 17, 2020.
The development of a new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry serious side effects and often do not offer a long-term cure.1 In the United States in 2018, there were an estimated 164,690 new cases of prostate cancer and more than 29,000 deaths occurred due to this cancer.2 Approximately 3.3 million U.S. men have prostate cancer in total. Worldwide in 2018, an estimated 1.28 million new cases of and nearly 360,000 deaths occurred due to this cancer.3
Advancements on the Horizon for Prostate Cancer
On July 29, 2019, INOVIO announced that as part of its clinical collaboration agreement with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI), INOVIO’s prostate cancer immunotherapy INO-5151 will be combined with an immune modulator (CDX-301, FLT3 ligand, a dendritic cell mobilizer) and a PD-1 checkpoint inhibitor (nivolumab) targeting metastatic castration resistant prostate cancer (mCRPC) in a PICI sponsored platform study. The trial is expected to complete enrollment in 2020.
American Cancer Society. Considering Prostate Cancer Treatment Options. Available at: cancer.org. Accessed April 3, 2020.
Siegel RL, Miller KD, Jemal A. Cancer Statistics 2018. CA Cancer J Clin 2018;68:7‐30.
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89. doi:10.14740/wjon1191
© Copyright 2020 INOVIO Pharmaceuticals. All rights reserved.